Scott Rocklage, Ph.D. started working at 5AM Ventures in 2003 as a Partner and rose to the role of Managing Partner a year later. Dr. Rocklage has a 30-year experience in healthcare management with tactical leadership roles that led to FDA approval of new drug applications (Teslascan® Omniscan™, and Cubicin®).
Dr. Rocklage has served as CEO and Chairman of Cubist Pharmaceuticals, CEO and President of Nycomed Salutar and also as R&D at Catalytica and Salutar. He previously served as Board Chairman of Relypsa and Novira. He currently serves as Board Chairman of Kinestral, Rennovia, and Cidara as well as Epirus and Pulmatrix. Dr. Rocklage was a former Management Chairman of Ilypsa (Amgen), Miikana (now EntreMed) and Semprus (Teleflex).
Dr. Scott Rocklage acquired his B.S. in Chemistry from UCB and his Chemistry Ph.D. from MIT, where he researched under the guidance of Richard R. Schrock (Nobel winner – 2005). He has invented over 30 government patents and reviewed over 100 peer-publications. Dr. Rocklage currently operates from his Boston, MA, office.
The Rocklages’ Unexpected Science Lab Gift
On July 18, 2016, Dr. Scott Rocklage was invited by his former Chemistry research institution. He was to celebrate the unexpected gift to the Chemistry Department in support of the renovation of Moungi Bawendi’s nanochemistry and nanotechnology lab space at MIT. Dr. Rocklage conducted his Ph.D. thesis in the Department of Chemistry under the guidance of Professor Richard R. Schrock, a 2005 Chemistry Nobel laureate.
Dr.Scott Rocklage and his wife Patty got a tour of the newly revamped lab space by a resident Professor Bawendi and a few graduate students. He was pleasantly surprised to find a plaque with his name inscribed on it at the Lab’s entrance. The entire chemistry department staff witnessed as Dr. Rocklage received accolades from the Bawendi members, former department heads Timothy Jamison, Sylvia Ceyer, and Prof. Moungi Bawendi.
5AM Ventures is a top investment firm whose aim is to build future science companies competent to deliver exceptional profits to investors. 5AM Ventures supports businesses that work to resolve healthcare needs through advanced research in medicine. The groups of companies involved lead with innovative approaches to recognize, avert and treat a broad range of health conditions.
5AM’s venture experts hold competitive financial, scientific, operational, medical, and legal skills. The balanced background gives the firm a unique advantage to discover and outline life science group companies. They employ seasoned, hands-on approach to growth and also get directly involved in applying business strategy, executive recruiting, and fundraising. The sitting board members regularly take on interim operating roles.
Dr.Scott Rocklage has spent his career in the life science profession, often working jointly with other like-minded peers to help generate shareholder value. As a board management leader, Dr. Rocklage draws over thirty years of CEO and added leadership roles at various science companies. He has proven to be fully capable of working with established investors, and co-investing with venture capitalists at major science companies.